Technical Analysis for BMY - Bristol-Myers Squibb Company

Grade Last Price % Change Price Change
grade F 43.33 -1.63% -0.72
BMY closed down 1.63 percent on Friday, July 19, 2019, on approximately normal volume. The bears made the stock sink to a new 52-week low. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Earnings due: Jul 25

*** please verify all earnings dates ***

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical BMY trend table...

Date Alert Name Type % Chg
New 52 Week Closing Low Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
New 52 Week Low Weakness 0.00%
Down 3 Days in a Row Weakness 0.00%
Oversold Stochastic Weakness 0.00%
New 52 Week Closing Low Bearish -1.63%
Hammer Candlestick Bullish -1.63%
Lizard Bullish Bullish Day Trade Setup -1.63%
New 52 Week Low Weakness -1.63%
Oversold Stochastic Weakness -1.63%

Older signals for BMY ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Its principal products include Plavix for protection against fatal or non-fatal heart attack or stroke; Avapro/Avalide for the treatment of hypertension and diabetic nephropathy; Eliquis to prevent and treat venous thromboembolic disorders and stroke prevention in atrial fibrillation; Abilify, an agent for adult patients with schizophrenia, bipolar mania disorder, and depressive disorder; and Reyataz and Sustiva to treat human immunodeficiency virus. The company's products also include Baraclude, an inhibitor of hepatitis B virus; Erbitux to target and block the epidermal growth factor receptor; Sprycel for treatment of chronic myeloid leukemia in adults; Yervoy to treat metastatic melanoma; Orencia to treat adult patients with moderate to severe rheumatoid arthritis; Nulojix to prevent kidney transplant rejection; Onglyza/Kombiglyze, Byetta, and Bydureon to treat type 2 diabetes; and Forxiga for the treatment of diabetes. Its products under Phase III clinical trials include Asunaprevir and Daclatasvir, which are oral small molecule to treat hepatitis C virus infection; Peginterferon lambda, a novel type 3 interferon for hepatitis C virus infection; Elotuzumab for multiple myeloma; and Nivolumab, an anticancer treatment, as well as products under the registrational process comprises Metreleptin for the treatment of lipodystrophy. The company sells its products to wholesalers, as well as directly to distributors, retailers, hospitals, clinics, government agencies, and pharmacies. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.
Chemistry Biopharmaceutical Diabetes Organic Chemistry Schizophrenia Multiple Myeloma Serious Diseases Hypertension Diabetic Nephropathy Treatment Of Diabetes Atrial Fibrillation Bristol Myers Squibb Metastatic Melanoma Stroke Hepatitis C Virus Infection Biopharmaceutical Products Depressive Disorder Chronic Myeloid Leukemia Kidney Transplant Treatment Of Hypertension
Is BMY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 63.69
52 Week Low 43.26
Average Volume 12,415,534
200-Day Moving Average 49.6408
50-Day Moving Average 46.282
20-Day Moving Average 45.4095
10-Day Moving Average 44.672
Average True Range 0.8385
ADX 24.28
+DI 13.96
-DI 34.4354
Chandelier Exit (Long, 3 ATRs ) 47.0345
Chandelier Exit (Short, 3 ATRs ) 45.7755
Upper Bollinger Band 47.9736
Lower Bollinger Band 42.8454
Percent B (%b) 0.09
BandWidth 11.293232
MACD Line -0.7675
MACD Signal Line -0.5454
MACD Histogram -0.2221
Fundamentals Value
Market Cap 71.06 Billion
Num Shares 1.64 Billion
EPS 2.74
Price-to-Earnings (P/E) Ratio 15.81
Price-to-Sales 4.94
Price-to-Book 6.80
PEG Ratio 1.93
Dividend 1.56
Dividend Yield 3.60%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 44.73
Resistance 3 (R3) 44.86 44.52 44.49
Resistance 2 (R2) 44.52 44.17 44.46 44.41
Resistance 1 (R1) 43.93 43.95 43.76 43.80 44.34
Pivot Point 43.59 43.59 43.51 43.53 43.59
Support 1 (S1) 43.00 43.24 42.83 42.87 42.32
Support 2 (S2) 42.66 43.02 42.60 42.25
Support 3 (S3) 42.07 42.66 42.17
Support 4 (S4) 41.94